sorafenib has been researched along with arctigenin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (arctigenin) | Trials (arctigenin) | Recent Studies (post-2010) (arctigenin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 283 | 1 | 231 |
| Protein | Taxonomy | sorafenib (IC50) | arctigenin (IC50) |
|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, D; Xu, M; Zhou, G | 1 |
1 other study(ies) available for sorafenib and arctigenin
| Article | Year |
|---|---|
Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorouracil; Humans; Kidney Neoplasms; Mice; rhoA GTP-Binding Protein; Sorafenib | 2023 |